Commensal Clostridiales strains mediate effective anti-cancer immune response against solid tumors.
Clostridiales
cancer
colorectal cancer
gut microbiota
immunotherapy
solid tumors
tumor models
tumor therapy
Journal
Cell host & microbe
ISSN: 1934-6069
Titre abrégé: Cell Host Microbe
Pays: United States
ID NLM: 101302316
Informations de publication
Date de publication:
13 10 2021
13 10 2021
Historique:
received:
08
03
2021
revised:
16
06
2021
accepted:
03
08
2021
pubmed:
29
8
2021
medline:
10
2
2022
entrez:
28
8
2021
Statut:
ppublish
Résumé
Despite overall success, T cell checkpoint inhibitors for cancer treatment are still only efficient in a minority of patients. Recently, intestinal microbiota was found to critically modulate anti-cancer immunity and therapy response. Here, we identify Clostridiales members of the gut microbiota associated with a lower tumor burden in mouse models of colorectal cancer (CRC). Interestingly, these commensal species are also significantly reduced in CRC patients compared with healthy controls. Oral application of a mix of four Clostridiales strains (CC4) in mice prevented and even successfully treated CRC as stand-alone therapy. This effect depended on intratumoral infiltration and activation of CD8
Identifiants
pubmed: 34453895
pii: S1931-3128(21)00377-2
doi: 10.1016/j.chom.2021.08.001
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1573-1588.e7Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests M.S. and M.R.S. have shares in PharmaBiome. M.S. served as Advisor for Gilead, Fresenius, Topadur, Takeda, and Celltrion, and received speaker’s honoraria from Falk Pharma and Vifor Pharma. T.W. and L. Berchtold are employees of PharmaBiome. G.E.L. is also an employee of PharmaBiome. G.R. is member of the Board of Directors of PharmaBiome. A patent related to this work has been generated (PCT/EP2021/053390). This intellectual property is entirely owned by the University of Zürich.